Hookipa Pharma
Hookipa Pharma
HOOK
NASDAQ
5.23
USD
144.39%
About
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers.
Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 18.7K |
| Three Month Average Volume | 928.2K |
| High Low | |
| Fifty-Two Week High | 11.3 USD |
| Fifty-Two Week Low | 4.1 USD |
| Fifty-Two Week High Date | 21 Dec 2023 |
| Fifty-Two Week Low Date | 26 Oct 2023 |
| Price and Volume | |
| Current Price | 5.23 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.06% |
| Thirteen Week Relative Price Change | -38.46% |
| Twenty-Six Week Relative Price Change | -38.23% |
| Fifty-Two Week Relative Price Change | -36.28% |
| Year-to-Date Relative Price Change | -45.48% |
| Price Change | |
| One Day Price Change | 0.38% |
| Thirteen Week Price Change | -34.13% |
| Twenty-Six Week Price Change | -32.09% |
| Five Day Price Change | -1.69% |
| Fifty-Two Week Price Change | -20.15% |
| Year-to-Date Price Change | -35.43% |
| Month-to-Date Price Change | -10.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.45418 USD |
| Book Value Per Share (Most Recent Quarter) | 7.13955 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.45418 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 7.13955 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.43969 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.12945 USD |
| Revenue Per Share (Trailing Twelve Months) | 4.85417 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -8.63038 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.27778 USD |
| Normalized (Last Fiscal Year) | -7.75254 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -8.63038 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.27242 USD |
| Including Extraordinary Items (Last Fiscal Year) | -8.63038 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.27778 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 9.71382 USD |
| Cash Per Share (Most Recent Quarter) | 6.40008 USD |
| Cash Flow Per Share (Last Fiscal Year) | -8.25461 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.23199 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -7.20974 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -297 |
| Cash Flow Revenue (Trailing Twelve Months) | -149 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -92.85% |
| Pretax Margin (Last Fiscal Year) | -403.46% |
| Pretax Margin (5 Year) | -365.94% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -485.34% |
| Operating Margin (Trailing Twelve Months) | -124.45% |
| Operating Margin (5 Year) | -423.10% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -405.29% |
| Net Profit Margin (Trailing Twelve Months) | -93.16% |
| Net Profit Margin (5 Year) | -366.65% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 0.07% |
| Tangible Book Value (5 Year) | 15.14% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -51.85% |
| Revenue Growth (3 Year) | 21.41% |
| Revenue Change (Trailing Twelve Months) | 227.80% |
| Revenue Per Share Growth | -6.64% |
| Revenue Growth (5 Year) | 0.92% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 14.11% |
| Total Debt (5 Year) | -23.91% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 30.09% |
| EPS Change (Trailing Twelve Months) | 51.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -77,150,000 |
| Net Debt (Last Fiscal Year) | -115,976,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -61,683,000 |
| Free Cash Flow (Trailing Twelve Months) | -77,476,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -49.18% |
| Return on Assets (Trailing Twelve Months) | -30.74% |
| Return on Assets (5 Year) | -41.63% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -84.81% |
| Return on Equity (Trailing Twelve Months) | -48.99% |
| Return on Equity (5 Year) | -64.32% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -64.19% |
| Return on Investment (Trailing Twelve Months) | -40.15% |
| Return on Investment (5 Year) | -50.26% |